Goodnough et al1 are to be commended for drawing attention to the impressive body of literature that documents the deleterious direct effects of anemia. Admittedly, anemia is ubiquitous and undertreated. However, the authors' statement that currently existing perisurgical transfusion guidelines "may misguide clinicians and underserve patients"1 is not substantiated. Most studies they reference examined patients with progressive chronic medical conditions such as malignancy, congestive heart failure, and renal failure and are not applicable to surgical patients, a substantial percentage of whom are acutely ill. Of note, the study2 they allude to that "suggests . . . mild anemia may be an independent risk factor for death following general surgery"1 did not explicitly characterize patients by severity of illness, was observational in design, and does not address whether measures implemented to correct the anemia would impact any increased risk. The last point is of particular import, for while there is certainly a role for use of erythropoietin and intraoperative cell salvage techniques in surgical patients, currently, the primary means of treating anemia in the perioperative period is transfusion of allogenic packed red blood cells. This intervention is clearly appropriate in certain circumstances (ie, resuscitating overt hemorrhage or augmenting end-organ oxygen delivery when there is clinical evidence of ischemia), but there is an increasing realization that the risks of transfusion often outweigh its benefits. Transfusion carries a well-described inherent infectious risk,3 is associated with an increased rate of nosocomial infection,4 can precipitate hemolytic or nonhemolytic reactions, and may induce harmful immunomodulation.5 Transfusion-related acute lung injury, a potentially fatal condition, appears to occur most commonly in the perioperative period.6 In addition, there are data suggesting that anemia may be well tolerated in critically ill postoperative patients7 and in patients undergoing vascular surgery,8 elective coronary artery bypass graft surgery,9,10 and mitral valve surgery.11 Given the current evidence, until additional prospective studies examine outcomes in surgical populations, any revision of perisurgical transfusion guidelines that would liberalize administration of allogenic packed red blood cells is premature.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.